https://www.wsj.com/articles/an-fda-breakthrough-on-treatment-11585609832?mod=opinion_lead_pos2
The Food and Drug Administration on Sunday green-lighted two malaria medicines that have shown some promise treating the novel coronavirus, and the emergency approvals couldn’t come soon enough. Expanding their use could bring quicker relief to patients and hospitals while allowing scientists to better assess their efficacy.
The malaria drugs hydroxychloroquine (HC) and chloroquine have been around for more than five decades, so their safety is well documented. New evidence suggests that they could also help fight the novel coronavirus, as op-eds by Dr. Jeff Colyer on these pages have reported. Both chloroquine and HC in vitro block the replication of RNA viruses like the novel coronavirus.
Hydroxychloroquine nowadays is often prescribed for the autoimmune conditions lupus and rheumatoid arthritis that result from the body’s immune system attacking its own cells. Scientists have also documented an overreactive immune response in severely ill coronavirus patients.
Notably, a study in France of 80 coronavirus patients given HC and azithromycin, an antibiotic for upper respiratory infections, documented “a clinical improvement in all but one 86 year-old patient who died, and one 74 year-old patient still in intensive care unit.” Doctors have also reported anecdotal evidence of the malaria drugs’ efficacy.